Tildrakizumab efficacy by metabolic syndrome status in psoriasis: Post hoc analysis of 3-year data from the phase 3 reSURFACE 1 study

被引：0
|
作者：
Lebwohl, Mark G. [1 ]
Gottlieb, Alice B. [2 ]
Mendelsohn, Alan M. [3 ]
Parno, Jeff [3 ]
Rozzo, Stephen J. [4 ]
Menter, Martin [5 ]
机构：
[1] Mt Sinai Hosp, Dept Dermatol, New York, NY 10029 USA
[2] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[3] Sun Pharmaceut, Mumbai, Maharashtra, India
[4] Sun Pharmaceut Ind, Mumbai, Maharashtra, India
[5] Baylor Scott & White, Dallas, TX USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2020年 / 83卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
15938
引用
收藏
页码：AB51 / AB51
页数：1
相关论文
共 50 条
  • [31] Time to relapse in patients with moderate to severe psoriasis who were tildrakizumab responders at week 28: Post hoc analysis through 64 weeks from the reSURFACE 1 trial
    Reich, Kristian
    Carrascosa, Jose-Manuel
    Fumero, Emilio
    Schoenenberger Lopez, Andreu
    Lebwohl, Mark
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB11 - AB11
  • [32] Low incidence rate of respiratory and viral infections over 5 years of treatment with tildrakizumab in patients with moderate-to-severe psoriasis: pooled analysis from reSURFACE 1 and reSURFACE 2 phase 3 trials
    Thaci, D.
    Jullien, D.
    Egeberg, A.
    Carrascosa, J. M.
    Wu, J. J.
    Pau-Charles, I.
    Gisondi, P.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (11) : E709 - E711
  • [33] Tildrakizumab Efficacy on Psoriasis in Patients with Psoriatic Arthritis-An Analysis from a Phase 2 Study
    Gottlieb, Alice
    Orbai, Ana-Maria
    Ballerini, Rocco
    Chou, Richard C.
    Rozzo, Stephen
    Mendelsohn, Alan
    Espinoza, Luis R.
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [34] Tildrakizumab efficacy on psoriasis in patients with psoriatic arthritis-an analysis from a phase 2 study
    Gottlieb, A. B.
    Ballerini, R.
    Chou, R. C.
    Rozzo, S. J.
    Rozzo, S.
    Espinoza, L. R.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2021, 62 : 44 - 44
  • [35] Tofacitinib in Patients With Psoriatic Arthritis and Metabolic Syndrome: A Post hoc Analysis of Phase 3 Studies
    Ritchlin, Christopher T.
    Giles, Jon T.
    Ogdie, Alexis
    Gomez-Reino, Juan J.
    Helliwell, Philip
    Young, Pamela
    Wang, Cunshan
    Wu, Joseph
    Romero, Ana Belen
    Woolcott, John
    Stockert, Lori
    ACR OPEN RHEUMATOLOGY, 2020, 2 (10) : 543 - 554
  • [36] Long-term stability of PASI <3 response to tildrakizumab: Pooled analyses from reSURFACE 1 and reSURFACE 2 phase 3 trials through 5 years
    Thaci, Diamant
    Piaserico, Stefano
    Du Jardin, Kristian Gaarn
    Warren, Richard B.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023, 37 (04) : E501 - E504
  • [37] 3-year myopia control efficacy can be predicted from 1-year data
    Brennan, Noel A.
    Cheng, Xu
    Bullimore, Mark A.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2024, 65 (07)
  • [38] Association of Smoking Status with Incidental Metabolic Syndrome in Men; a 3-year Follow-up Study
    Kim, Byung Jin
    Sung, Ki Chul
    Kim, Bum Soo
    Kong, Jin Ho
    Lee, Man Ho
    CIRCULATION, 2008, 118 (18) : S1082 - S1082
  • [39] Analysis of 3-year national reimbursement application data on etanercept and efalizumab for psoriasis
    Driessen, R. J. B.
    de Jong, E. M. G. J.
    de Rie, M. A.
    Salemink, G. W.
    van de Kerkhof, P. C. M.
    BRITISH JOURNAL OF DERMATOLOGY, 2008, 159 (03) : 760 - 761
  • [40] Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)
    Thaci, D.
    Piaserico, S.
    Warren, R. B.
    Gupta, A. K.
    Cantrell, W.
    Draelos, Z.
    Foley, P.
    Igarashi, A.
    Langley, R. G.
    Asahina, A.
    Young, M.
    Falques, M.
    Pau-Charles, I.
    Mendelsohn, A. M.
    Rozzo, S. J.
    Reich, K.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (02) : 323 - 334
12345